Tau-PET and in vivo Braak-staging as prognostic markers of future cognitive decline in cognitively normal to demented individuals
Abstract Background To systematically examine the clinical utility of tau-PET and Braak-staging as prognostic markers of future cognitive decline in older adults with and without cognitive impairment. Methods In this longitudinal study, we included 396 cognitively normal to dementia subjects with 18...
Main Authors: | Davina Biel, Matthias Brendel, Anna Rubinski, Katharina Buerger, Daniel Janowitz, Martin Dichgans, Nicolai Franzmeier, for the Alzheimer’s Disease Neuroimaging Initiative (ADNI) |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2021-08-01
|
Series: | Alzheimer’s Research & Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13195-021-00880-x |
Similar Items
-
FDG-PET hypermetabolism is associated with higher tau-PET in mild cognitive impairment at low amyloid-PET levels
by: Anna Rubinski, et al.
Published: (2020-10-01) -
Multicenter <sup>18</sup>F-PI-2620 PET for In Vivo Braak Staging of Tau Pathology in Alzheimer’s Disease
by: Michael Rullmann, et al.
Published: (2022-03-01) -
Higher levels of myelin are associated with higher resistance against tau pathology in Alzheimer’s disease
by: Anna Rubinski, et al.
Published: (2022-09-01) -
Combining tau-PET and fMRI meta-analyses for patient-centered prediction of cognitive decline in Alzheimer’s disease
by: Davina Biel, et al.
Published: (2022-11-01) -
Predicting cognitive dysfunction and regional hubs using Braak staging amyloid-beta biomarkers and machine learning
by: Puskar Bhattarai, et al.
Published: (2023-12-01)